Beta Drugs Ltd
: BETA · Pharmaceuticals
Snapshot
Unlock Beta Drugs Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Beta Drugs Ltd is an Indian pharmaceutical company specialising in the manufacturing of a diverse range of oncology drugs. The company maintains a strong market position, ranking among the top 10 oncology-focused firms in India.
Business Model
The company generates revenue through the production and sale of anti-cancer pharmaceutical products across both domestic and international markets. It leverages a portfolio where several key products hold leading market rankings in their respective categories.
- Market Position:Top 10 oncology company
Growth Outlook
Growth is driven by the company's established presence in the oncology segment and its focus on maintaining high-ranking product categories. Expansion efforts continue across both domestic and export markets.
Key Risks
- Regulatory Risk. The pharmaceutical industry is subject to stringent government regulations and quality control standards that can impact manufacturing operations.
- Concentration Risk. A heavy focus on the oncology segment makes the company vulnerable to shifts in cancer treatment trends or pricing pressures within that specific therapeutic area.
- Competitive Intensity. The oncology market is highly competitive, requiring continuous investment in product development to maintain market share against established domestic and global players.
Start your research today
Unlock AI insights, financials, peers and live data on Beta Drugs Ltd and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Beta Drugs LtdBETA | ₹2,459 Cr | — | — | — | 20.0% | — | — | +17.7% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,432 Cr | 20.00 | 27.39 | — | 14.9% | 21.3% | 40.9% | +15.0% |
Indoco RemediesINDOCO | ₹2,423 Cr | 820.34 | 20.29 | 12.1% | 9.0% | 0.3% | 8.4% | -3.9% |
Windlas BiotechWINDLAS | ₹2,377 Cr | 35.61 | 19.64 | 18.5% | 13.0% | 12.2% | 16.8% | +14.5% |
Panacea BiotecPANACEABIO | ₹2,335 Cr | -328.66 | 130.32 | 10.3% | 2.6% | -1.1% | -0.4% | -6.4% |
Sai Parenterals LimitedSAIPARENT | ₹2,295 Cr | — | — | — | 10.0% | — | — | — |
As of Mar 2026
Financials
Beta Drugs Ltd
: BETA · Pharmaceuticals
Snapshot
Unlock Beta Drugs Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Beta Drugs Ltd is an Indian pharmaceutical company specialising in the manufacturing of a diverse range of oncology drugs. The company maintains a strong market position, ranking among the top 10 oncology-focused firms in India.
Business Model
The company generates revenue through the production and sale of anti-cancer pharmaceutical products across both domestic and international markets. It leverages a portfolio where several key products hold leading market rankings in their respective categories.
- Market Position:Top 10 oncology company
Growth Outlook
Growth is driven by the company's established presence in the oncology segment and its focus on maintaining high-ranking product categories. Expansion efforts continue across both domestic and export markets.
Key Risks
- Regulatory Risk. The pharmaceutical industry is subject to stringent government regulations and quality control standards that can impact manufacturing operations.
- Concentration Risk. A heavy focus on the oncology segment makes the company vulnerable to shifts in cancer treatment trends or pricing pressures within that specific therapeutic area.
- Competitive Intensity. The oncology market is highly competitive, requiring continuous investment in product development to maintain market share against established domestic and global players.
Start your research today
Unlock AI insights, financials, peers and live data on Beta Drugs Ltd and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026